Pierre-Michel Bringer
CEO of StartAge Therapeutics
Pierre-Michel is the CEO of StartAge Therapeutics, with more than 35 years of expertise in pharmaceutic industry in many countries. His services inclde M&A / licensing, communication, strategic planning, marketing & sales. Previously, he worked as Investor Relations Officer with Novartis.
Pierre-Michel holds a Doctorate of Pharmacy from Université de Paris.
Visit website: https://starkagetx.com/team-member/pierre-michel-bringer/
See also: 
StarkAge Therapeutics
- Pioneering biotechnology company with relentless focus on senescence
Details last updated 22-Jan-2022
Pierre-Michel Bringer News
Benjamin Le Calvé as the new Chief Scientific Officer of Starkage Therapeutics
StarkAge Therapeutics - 10-May-2022
Le Calvé will chair the Scientific Advisory Board and the Management Committee
Read more...StarkAge receives 2 million euros to design safer senescence-targeted therapies
Longevity Technology - 19-Jan-2022
Funding will ensure the development of a new immunotherapy for age-related diseases
Read more...
